Alpha-2 macroglobulin (A2M) is a plasma protein in the blood that occurs naturally in the human body.
A2M regulates the immune system to prevent the destruction of cells that produce cartilage. The patient’s blood is drawn, then the A2M is extracted, processed, and injected into the target joints. This treatment prevents the degeneration of joint cartilage and is often used in the case of a diagnosis of osteoarthritis or after an injury that might result in osteoarthritis, such as a ruptured ligament.
Prevent Joint-Cartilage Breakdown
Based on highly promising recent studies, A2M appears to be the only existing molecule that can completely stop the development of osteoarthritis.
Indeed, A2M prevents joint cartilage from breaking down. Results from the preliminary studies have been positive, and the FDA (the United States’ agency regulating medical products) is supporting the development of this new technology.
Most patients require an injection every 6 to 12 months in order to stop osteoarthritis on a continuing basis.
Please note that Alpha-2 macroglobulin treatments are not covered most insurance companies, including Ontario Health Insurance Plan (OHIP). However, on a case-by-case basis, they may be covered by auto injury insurance (MVA) or worker’s injury insurance (WSIB). Contact us for more information regarding coverage options.
This treatment will soon be available at Inovo Medical. For more information, please contact us at: 613 749-4668